Human Liver Glycogen Phosphorylase Inhibitors
Journal of Medicinal Chemistry, 2005, Vol. 48, No. 20 6193
(3) Treadway, J. L.; Mendys, P.; Hoover, D. J. Glycogen phospho-
rylase inhibitors for treatment of type 2 diabetes mellitus.
Expert. Opin. Invest. Drugs 2001, 10, 439-454.
tion of heterocyclylbenzoylureas for treating type 2 diabetes.
WO2004007455.
(23) Defossa, E.; Kadereit, D.; Klabunde, T.; Burger, H.-J.; Herling,
A.; Wendt, K.-U.; Von Roedern, E.; Schoenafinger, K. Prepara-
tion of N-[(phenylamino)carbonyl]benzamides as glycogen-
phosphorylase-A inhibitors for the treatment of diabetes.
WO2004007437.
(24) Defossa, E.; Kadereit, D.; Klabunde, T.; Burger, H.-J.; Herling,
A.; Wendt, K.-U.; Von Roedern, E.; Schoenafinger, K.; Enhsen,
A. Method for the production of carbonylamino substituted acyl
phenyl urea derivatives, and use thereof in treating type 2
diabetes. WO2004065356.
(25) The limitation of a 3D pharmacophore model is that it does not
capture electrostatic interactions in a quantitative manner, e.g.
charge-supported hydrogen bonds are not distinguished from
normal hydrogen bonds. Also repulsive electrostatic interactions
are not taken into account for pharmacophore-based predictions
of biological activity. Using the 3D pharmacophore for a quan-
titative prediction of the biological activity for the indole
compound 44, the tetrahydrochinolin compound 45, and com-
pound 28 (Y5 NO2 group) is thus not possible. 3D QSAR models
are necessary to capture electrostatic and hydrophobic interac-
tions in a quantitative manner and have been used in addition
to the 3D pharmacophore to guide the chemical optimization.
(26) Kruszynska, Y. T. Normal metabolism: The physiology of fuel
homeostasis. In Textbook of Diabetes; Pickup, J. C., Williams,
G., Eds.; 2nd ed.; Blackwell Sciences: Oxford, 1998; Volume 1,
pp 11.1-11.37. Textbook of Diabetes, 2nd ed.; Pickup, J. C. W.
G. e., Ed.; Blackwell Sciences: Oxford, 2005; pp 1-37.
(27) Catalyst, version 4.7; Accelrys Inc.: San Diego, CA, 2002.
(28) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.;
Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W.
C. Macromodel-An Integrated Software System for Modeling
Organic and Bioorganic Molecules using Molecular Mechanics.
J. Comput. Chem. 1990, 11, 440-445.
(29) Halgren, T. A. MMFF VII. Characterization of MMFF94,
MMFF94s, and other widely available force fields for conforma-
tional energies and for intermolecular-interaction energies and
geometries. J. Comput. Chem. 1999, 20, 730-738.
(30) For cost analysis, see Catalyst 4.7 documentation at www.
accelrys.com/doc/life/catalyst47/help/HypoGenAlgRef.doc.html.
(31) SYBYL, version 6.9; Tripos, Inc.: St. Louis, MO, 2003.
(32) Fischer, E. H.; Krebs, E. G. Muscle phosphorylase b. Methods
Enzymol. 1962, 5, 369-372.
(33) Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data
collected in oscillation mode. Methods Enzymol. 1997, 307-326.
(34) Oikonomakos, N. G. unpublished results. 2004.
(35) Brunger, A. T. X-PLOR: version 3.8, a system for protein
crystallography and NMR. 2004; Yale University Press: New
Haven, CT.
(36) Jones, T. A.; Zou, J. Y.; Cowan, S. W. Kjeldgaard Improved
methods for building protein models in electron density maps
and the location of errors in these models. Acta Crystallogr. A
1991, 47 (Pt 2), 110-119.
(37) Kabsch, W. Automatic processing of rotation diffraction data
from crystals of initially unknown symmetry and cell constants.
J. Appl. Crystallogr. 2004, 26, 795-800.
(38) Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros,
P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges,
M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren,
G. L. Crystallography & NMR system: A new software suite
for macromolecular structure determination. Acta Crystallogr.
D. Biol. Crystallogr. 1998, 54 (Pt 5), 905-921.
(39) Quanta: Molecular Simulations Inc., San Diego, CA.
(41) Drueckes, P.; Schinzel, R.; Palm, D. Photometric microtiter assay
of inorganic phosphate in the presence of acid-labile organic
phosphates. Anal. Biochem. 1995, 230, 173-177.
(42) Schwab, D.; Herling, A. W.; Hemmerle, H.; Schubert, G.;
Hagenbuch, B.; Burger, H. J. Hepatic uptake of synthetic
chlorogenic acid derivatives by the organic anion transport
proteins. J. Pharmacol. Exp. Ther. 2001, 296, 91-98.
(43) Herling, A. W.; Burger, H. J.; Schwab, D.; Hemmerle, H.; Below,
P.; Schubert, G. Pharmacodynamic profile of a novel inhibitor
of the hepatic glucose-6-phosphatase system. Am. J. Physiol.
1998, 274, G1087-G1093.
(44) Ekstrom, J. L.; Pauly, T. A.; Carty, M. D.; Soeller, W. C.; Culp,
J.; Danley, D. E.; Hoover, D. J.; Treadway, J. L.; Gibbs, E. M.;
Fletterick, R. J.; Day, Y. S.; Myszka, D. G.; Rath, V. L.
Structure-activity analysis of the purine binding site of human
liver glycogen phosphorylase. Chem. Biol. 2002, 9, 915-924.
(4) Rath, V. L.; Ammirati, M.; LeMotte, P. K.; Fennell, K. F.;
Mansour, M. N.; Danley, D. E.; Hynes, T. R.; Schulte, G. K.;
Wasilko, D. J.; Pandit, J. Activation of human liver glycogen
phosphorylase by alteration of the secondary structure and
packing of the catalytic core. Mol. Cell 2000, 6, 139-148.
(5) Newgard, C. B.; Hwang, P. K.; Fletterick, R. J. The family of
glycogen phosphorylases: Structure and function. Crit Rev.
Biochem. Mol. Biol. 1989, 24, 69-99.
(6) Gregoriou, M.; Noble, M. E.; Watson, K. A.; Garman, E. F.;
Krulle, T. M.; de la, F. C.; Fleet, G. W.; Oikonomakos, N. G.;
Johnson, L. N. The structure of a glycogen phosphorylase
glucopyranose spirohydantoin complex at 1.8 A resolution and
100 K: The role of the water structure and its contribution to
binding. Protein Sci. 1998, 7, 915-927.
(7) Zographos, S. E.; Oikonomakos, N. G.; Tsitsanou, K. E.; Le-
onidas, D. D.; Chrysina, E. D.; Skamnaki, V. T.; Bischoff, H.;
Goldmann, S.; Watson, K. A.; Johnson, L. N. The structure of
glycogen phosphorylase b with an alkyldihydropyridine-dicar-
boxylic acid compound, a novel and potent inhibitor. Structure
1997, 5, 1413-1425.
(8) Lu, Z.; Bohn, J.; Bergeron, R.; Deng, Q.; Ellsworth, K. P.;
Geissler, W. M.; Harris, G.; McCann, P. E.; McKeever, B.; Myers,
R. W.; Saperstein, R.; Willoughby, C. A.; Yao, J.; Chapman, K.
A new class of glycogen phosphorylase inhibitors. Bioorg. Med.
Chem. Lett. 2003, 13, 4125-4128.
(9) Kristiansen, M.; Andersen, B.; Iversen, L. F.; Westergaard, N.
Identification, synthesis, and characterization of new glycogen
phosphorylase inhibitors binding to the allosteric AMP site. J.
Med. Chem. 2004, 47, 3537-3545.
(10) Oikonomakos, N. G.; Schnier, J. B.; Zographos, S. E.; Skamnaki,
V. T.; Tsitsanou, K. E.; Johnson, L. N. Flavopiridol inhibits
glycogen phosphorylase by binding at the inhibitor site. J. Biol.
Chem. 2000, 275, 34566-34573.
(11) Oikonomakos, N. G.; Skamnaki, V. T.; Tsitsanou, K. E.; Gavalas,
N. G.; Johnson, L. N. A new allosteric site in glycogen phos-
phorylase b as a target for drug interactions. Structure. Fold.
Des. 2000, 8, 575-584.
(12) Rath, V. L.; Ammirati, M.; Danley, D. E.; Ekstrom, J. L.; Gibbs,
E. M.; Hynes, T. R.; Mathiowetz, A. M.; McPherson, R. K.; Olson,
T. V.; Treadway, J. L.; Hoover, D. J. Human liver glycogen
phosphorylase inhibitors bind at a new allosteric site. Chem.
Biol. 2000, 7, 677-682.
(13) Hoover, D. J.; Lefkowitz-Snow, S.; Burgess-Henry, J. L.; Martin,
W. H.; Armento, S. J.; Stock, I. A.; McPherson, R. K.; Genereux,
P. E.; Gibbs, E. M.; Treadway, J. L. Indole-2-carboxamide
inhibitors of human liver glycogen phosphorylase. J. Med. Chem.
1998, 41, 2934-2938.
(14) Martin, W. H.; Hoover, D. J.; Armento, S. J.; Stock, I. A.;
McPherson, R. K.; Danley, D. E.; Stevenson, R. W.; Barrett, E.
J.; Treadway, J. L. Discovery of a human liver glycogen phos-
phorylase inhibitor that lowers blood glucose in vivo. Proc. Natl.
Acad. Sci. U.S.A. 1998, 95, 1776-1781.
(15) Oikonomakos, N. G.; Chrysina, E. D.; Kosmopoulou, M. N.;
Leonidas, D. D. Crystal structure of rabbit muscle glycogen
phosphorylase a in complex with a potential hypoglycaemic drug
at 2.0 A resolution. Biochim. Biophys. Acta 2003, 1647, 325-
332.
(16) Weikert, R. J.; Bingham, S., Jr; Emanuel, M. A.; Fraser-Smith,
E. B.; Loughhead, D. G.; Nelson, P. H.; Poulton, A. L. Synthesis
and anthelmintic activity of 3′-benzoylurea derivatives of 6-phenyl-
2,3,5,6-tetrahydroimidazo[2,1-b]thiazole. J. Med. Chem. 1991,
34, 1630-1633.
(17) Speziale, A. J.; Smith, L. R.; Fedder, J. E. The reaction of oxalyl
chloride with amides. IV. Synthesis of Acyl Isocyanates. J. Org.
Chem. 1965, 30, 4306-4307.
(18) Speziale, A. J.; Smith, L. R. The reaction of Oxalyl Chloride with
Amides. II. Oxazolidindiones and Acylisocyanates. J. Org. Chem.
1963, 28, 1805-1811.
(19) Schroth, W.; Krieg, R.; Kluge, H.; Gaebler, M. Synthesis of
aromatic acylisocyanates by thermolysis of 1,1-diacyl-3,3-dialkyl-
ureas. Z. Chem. 1985, 25, 398-399.
(20) Wiley, P. F. The reaction of amides with isocyanates. J. Am.
Chem. Soc. 1949, 1310-1311.
(21) Defossa, E.; Kadereit, D.; Schoenafinger, K.; Klabunde, T.;
Burger, H.-J.; Herling, A.; Wendt, K.-U.; Von Roedern, E.;
Enhsen, A.; Rieke-Zapp, J. Preparation of 4-(benzoylureido)-
benzoic acids as antidiabetics, WO2003084922.
(22) Schoenafinger, K.; Defossa, E.; Kadereit, D.; Von Roedern, E.;
Klabunde, T.; Burger, H.-J.; Herling, A.; Wendt, K.-U. Prepara-
JM049034Y